Graft-versus-myeloma effect: proof of principle

Blood. 1996 Feb 1;87(3):1196-8.

Abstract

The presence of a graft-versus-tumor effect has been well established in leukemia but not in multiple myeloma. A 40-year-old patient with myeloma refractory to standard chemotherapy and autologous transplantation received a matched unrelated T-cell-depleted transplant after conditioning with fractionated total-body irradiation, thiotepa, and cyclophosphamide. This procedure resulted in a transient and incomplete response with evidence of rapidly progressive disease within 2.5 months posttransplantation. The patient then received a small number of donor peripheral blood (PB) mononuclear cells (CD3 cells 1.2 x 10(6)/kg) without any further cytotoxic therapy. A complete remission was attained, lasting now for more than 14 months. The procedure was associated with severe acute and subsequently limited chronic graft-versus-host disease (GVHD). This report provides the first direct evidence of a graft-versus-myeloma effect after allogenic transplantation.

Publication types

  • Case Reports
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adult
  • Bone Marrow Transplantation*
  • CD3 Complex / analysis
  • Cyclophosphamide
  • Disease Progression
  • Female
  • Graft vs Host Disease / etiology
  • Graft vs Host Reaction*
  • Humans
  • Leukocyte Transfusion*
  • Lymphocyte Depletion
  • Multiple Myeloma / immunology
  • Multiple Myeloma / therapy*
  • Remission Induction
  • Salvage Therapy*
  • T-Lymphocyte Subsets / immunology
  • T-Lymphocyte Subsets / transplantation*
  • Thiotepa
  • Whole-Body Irradiation

Substances

  • CD3 Complex
  • Cyclophosphamide
  • Thiotepa